Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'

被引：0
|
作者：
Vivaldi, Caterina [1 ]
Fornaro, Lorenzo [1 ]
Caparello, Chiara [1 ]
Falcone, Alfredo [1 ]
Vasile, Enrico [1 ]
机构：
[1] Azienda Osped Univ Pisana, Polo Oncol, Via Roma 67, I-56126 Pisa, Italy
来源：
BRITISH JOURNAL OF CANCER | 2016年 / 114卷 / 11期
关键词：
CANCER;
D O I：
10.1038/bjc.2016.69
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e8 / e8
页数：1
相关论文
共 50 条
  • [31] Retrospective analysis of institutional outcomes with FOLFIRINOX versus nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Singh, Amisha
    Shroff, Rachna T.
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
    Rapposelli, Ilario Giovanni
    Casadei-Gardini, Andrea
    Vivaldi, Caterina
    Bartolini, Giulia
    Bernardini, Laura
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Massa, Valentina
    Cucchetti, Alessandro
    BIOMOLECULES, 2021, 11 (06)
  • [33] A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study
    Nakazawa, J.
    Otsuka, T.
    Shimokawa, M.
    Koga, F.
    Ueda, Y.
    Otsu, S.
    Arima, S.
    Fukahori, M.
    Makiyama, A.
    Taguchi, H.
    Honda, T.
    Shibuki, T.
    Shirakawa, T.
    Mitsugi, K.
    Nio, K.
    Ide, Y.
    Ureshino, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine plus nab-paclitaxel (NabG).
    Schmidt, Shannon Leah
    Durkal, Vipal
    Jayavalsan, Shinoj Pattali
    Thomas, James P.
    Ritch, Paul S.
    Erickson, Beth
    Christians, Kathleen K.
    Tsai, Susan
    Evans, Douglas B.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [35] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [36] Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study (Jan, 10.1038/s41416-022-01713-w, 2022)
    Zaibet, Sonia
    Hautefeuille, Vincent
    Auclin, Edouard
    Lievre, Astrid
    Tougeron, David
    Sarabi, Mathieu
    Gilabert, Marine
    Wasselin, Julie
    Edeline, Julien
    Artru, Pascal
    Bechade, Dominique
    Morin, Clemence
    Ducoulombier, Agnes
    Taieb, Julien
    Pernot, Simon
    BRITISH JOURNAL OF CANCER, 2022, 126 (06) : 969 - 969
  • [37] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Grierson, Patrick M.
    Tan, Benjamin
    Pedersen, Katrina S.
    Park, Haeseong
    Suresh, Rama
    Amin, Manik A.
    Trikalinos, Nikolaos A.
    Knoerzer, Deborah
    Kreider, Brent
    Reddy, Anupama
    Liu, Jingxia
    Der, Channing J.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    ONCOLOGIST, 2023, 28 (02): : E115 - E123
  • [38] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [39] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
  • [40] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Junko Tahara
    Kyoko Shimizu
    Nao Otsuka
    Junichi Akao
    Yukiko Takayama
    Katsutoshi Tokushige
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 245 - 250
12345